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Abstract Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anti-
cancer antibody-drug conjugate under development by Seattle Genetics Inc.
and its licensee Millennium: The Takeda Oncology Company. It comprises
the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic
agent monomethyl auristatin E, a synthetic analog of the tubulin polymer-
ization inhibitor dolastatin 10. It is under investigation for use in Hodgkin
lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell
lymphoma) in North America and Europe. This review discusses the key
development milestones and therapeutic trials of this drug.
1. Introduction
Brentuximab vedotin is an anticancer antibody-
drug conjugate (ADC) product under develop-
ment by Seattle Genetics Inc. (Bothell, WA, USA)
and its licensee Millennium: The Takeda Oncol-
ogy Company. The ADC comprises the anti-
CD30 monoclonal antibody cAC10 conjugated
to the cytotoxic agent monomethyl auristatin E
(MMAE), a synthetic analog of the tubulin poly-
merization inhibitor dolastatin 10. The chimeric
antibody is covalently coupled toMMAE through
a valine-citrulline peptide linker. Brentuximab ve-
dotin is designed to be stable in the bloodstream,
but to release MMAE upon internalization into
CD30-expressing tumor cells, resulting in a tar-
geted cell-killing effect. The CD30 antigen is
highly expressed by a variety of hematologic ma-
lignancies, including Hodgkin lymphoma and
some T-cell non-Hodgkin lymphomas. Clinical
development for the treatment of Hodgkin lym-
phoma and non-Hodgkin lymphoma (specifically
anaplastic large cell lymphoma [ALCL]) is being
conducted in North America and Europe.
1.1 Company Agreements
In December 2009, Seattle Genetics Inc. and
Millennium: The Takeda Oncology Company, a
wholly owned subsidiary of Takeda Pharma-
ceutical Company Limited, entered into a col-
laboration agreement to globally develop and
commercialize brentuximab vedotin. Under the
collaboration, Seattle Genetics Inc. will receive
an upfront payment of $US60million and retains
full commercialization rights for brentuximab
vedotin in the US and Canada. The Takeda
Group will have exclusive rights to commercialize
the product candidate in all countries other than
the US and Canada. Seattle Genetics Inc. is en-
titled to receive progress and sales-dependent
milestone payments in addition to tiered double-
digit royalties based on net sales of brentuximab
vedotin within the Takeda Group’s licensed
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territories. Milestone payments to Seattle Genetics
Inc. could total more than $US230million. Seattle
Genetics Inc. and the Takeda Group will jointly
fund worldwide development costs on a 50 : 50
basis. Development funding by the Takeda Group
over the first 3 years of the collaboration is ex-
pected to be at least $US75million. In Japan,
the Takeda Group will be solely responsible for
development costs.[1]
An agreement between Seattle Genetics Inc.
and Albany Molecular Research for the current
good manufacturing practice (cGMP) of its pro-
prietary drug-linker system was established in
May 2005. The arrangement also secures rights
for ADC licensees of Seattle Genetics Inc. to
work directly with AlbanyMolecular Research to
obtain cGMP clinical trial supplies of drug-linker
units.[2,3]
1.2 Key Development Milestones
Seattle Genetics Inc. plans to submit a bio-
logics license application (BLA) to theUSFDA in
the first quarter of 2011. The BLAwill aim to seek
approval for both relapsed or refractory Hodgkin
lymphoma and relapsed or refractory systemic
ALCL. In Europe, Millennium: The Takeda On-
cology Company has initiated discussions with
regulators to support the submission of a mar-
keting authorization application (MAA) to the
European Medicines Agency (EMA) in the first
half of 2011.[4]
The US FDA and the EMA have granted or-
phan drug designation to brentuximab vedotin
for the treatment of Hodgkin lymphoma and
ALCL (a type of non-Hodgkin lymphoma).[5,6] In
March 2009, the FDA granted fast-track desig-
nation to brentuximab vedotin for the treatment
of Hodgkin lymphoma.[7]
1.2.1 Hodgkin Lymphoma
Seattle Genetics Inc. and Millennium: The
Takeda Oncology Company have initiated a
phase III trial (AETHERA; NCT01100502) of
brentuximab vedotin in patients at high risk of
residual Hodgkin lymphoma following autolo-
gous stem cell transplant (ASCT). This random-
ized, double-blind, placebo-controlled trial is
evaluating the safety and efficacy of brentuximab
vedotin plus best supportive care (BSC) compared
with placebo plus BSC. Approximately 322 pa-
tients are being enrolled at sites in the US and
Europe. The primary outcome measure of the
trial is progression-free survival (PFS), and sec-
ondary outcomes measures include overall sur-
vival, safety, and tolerability. Patients will receive
brentuximab vedotin every 3 weeks for up to
approximately 1 year. For the purposes of the
trial, high-risk patients are defined as those with a
history of refractory Hodgkin lymphoma, those
who relapse or progress within 1 year of receiving
first-line chemotherapy, and/or those who have
disease outside of the lymph nodes at the time of
pre-ASCT relapse.[8] Interim results were pre-
sented in December 2010. Seattle Genetics Inc.
plans to submit a BLA in the first quarter of 2011
for approval of brentuximab vedotin in relapsed
or refractory Hodgkin lymphoma and systemic
ALCL.Millennium: The Takeda Oncology Com-
pany plans to submit an MAA in the first half of
2011. Additionally, a limited patient access pro-
gram for qualified patients will be set up in the
US in early 2011. Outside of the US and Canada,
brentuximab vedotin will be available to qualified
patients through a Named Patient Programme.[9]
Seattle Genetics Inc. and Millennium: The
Takeda Oncology Company initiated a phase II/
III study (NCT01196208) of brentuximab vedo-
tin in patients with Hodgkin lymphoma who re-
ceived placebo in the phase III AETHERA trial
(SGN35-0005). The trial expects to enroll up to
80 patients by invitation only and aims to be
completed by December 2011.
In February 2009, Seattle Genetics Inc. ini-
tiated a single-arm pivotal phase II trial (NCT
00848926) to assess the efficacy and safety of
single-agent brentuximab vedotin (1.8mg/kg
every 3 weeks) in 102 patients with relapsed or
refractory Hodgkin lymphoma under a special
protocol assessment agreement. The primary
endpoint of the study will be objective response
rate and secondary endpoints to include duration
of response, PFS, overall survival, and toler-
ability. The company completed enrollment of
patients at more than 30 sites in the US, Canada,
and Europe in August 2009. Top-line data were
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reported by Seattle Genetics Inc. and Millen-
nium: The Takeda Oncology Company in Sep-
tember 2010.[10]
In July 2009, Seattle Genetics Inc. initiated
a multicenter, phase II trial (NCT00947856)
investigating the efficacy and tolerability of re-
treatment with brentuximab vedotin (1.8mg/kg
every 3 weeks) in patients with relapsed or refrac-
tory Hodgkin lymphoma or systemic ALCL who
had previously responded to brentuximab vedo-
tin. The trial is expected to enroll 125 patients and
is taking place in the US and Europe.[11,12]
In January 2010, Seattle Genetics Inc. and
Millennium: The Takeda Oncology Company
initiated an open-label, single-arm phase I trial
(SGN35-009; NCT01060904) of brentuximab ve-
dotin in combination with ABVD (doxorubicin,
bleomycin, vinblastine and dacarbazine) in the
treatment of patients with newly diagnosed
Hodgkin’s lymphoma. The dose-escalation trial
will enroll 40 patients in the US and Canada.[13]
1.2.2 Non-Hodgkin Lymphoma (including Anaplastic
Large Cell Lymphoma)
In June 2009, Seattle Genetics Inc. initiated a
pivotal phase II study (NCT00866047) of single-
agent brentuximab vedotin (1.8mg/kg every 3
weeks) in patients with relapsed or refractory
systemic ALCL. Recruitment of 58 patients from
centers in the US, Canada, and the EU was
completed in May 2010. Preliminary, top-line
results have been reported.[14-17]
In July 2009, Seattle Genetics Inc. initiated
a multicenter, phase II trial (NCT00947856) in-
vestigating the efficacy and tolerability of re-
treatment with brentuximab vedotin (1.8mg/kg
every 3 weeks) in patients with systemic ALCL or
relapsed or refractory Hodgkin lymphoma who
had previously responded to brentuximab vedo-
tin. The trial is expected to enroll 125 patients and
is taking place in the US and Europe.[11,12]
1.2.3 General Hematologic Malignancies
Seattle Genetics Inc. has conducted a phase I
trial (NCT00430846) of brentuximab vedotin
(given every 21 days) in 44 refractory patients
with Hodgkin lymphoma or CD30-positive
hematologic malignancies. The trial evaluated
the safety and pharmacokinetics of brentuximab
vedotin among patients enrolled at multiple cen-
ters throughout the US. Data presented in De-
cember 2008 demonstrated multiple complete
and partial responses at well tolerated doses.[18-20]
Seattle Genetics Inc. and Millennium: The
Takeda Oncology Company are also conducting
a phase I study to assess the cardiac safety of
brentuximab vedotin in patients with CD30-
positive hematologic cancers (NCT01026233).[21]
The study was expected to be completed in Au-
gust 2010 but as of February 2011, the companies
have completed enrollment of 40 patients and the
trial is ongoing.
A phase I trial (NCT00649584) was initiated in
the US in March 2008, to evaluate brentuximab
vedotin in 72 patients with refractory or relapsed
CD30-positive hematologic malignancies (Hodgkin
lymphoma or systemic ALCL). The study was
expected to be completed in December 2010.
However, this trial was terminated as Seattle
Genetics Inc. decided not to enroll cohorts of
combined brentuximab vedotin and gemcitabine
therapy.[17,22-24]
1.3 Patent Information
The US Patent and Trademark Office has is-
sued Seattle Genetics Inc. with a patent related to
its ADC technology. US Patent No. 7 659241,
covers cleavable linkers and potent auristatin drug
payloads used in certain Seattle Genetics Inc.ADC
programs, including brentuximab vedotin.[25]
Seattle Genetics Inc. was issued a US patent
covering the cell-killing component of brentux-
imab vedotin in May 2005.[3]
2. Scientific Summary
2.1 Pharmacokinetics
Phase I : Area under the concentration-time
curve (AUC) increased relative to dose level of
brentuximab vedotin in this phase I trial. The trial
enrolled patients with relapsed or refractory CD30-
positive lymphomas (n = 37) and brentuximab
vedotin was administered weekly for 3 weeks in
28-day treatment cycles at doses of 0.4–1.4mg/kg
(30minute or 2 hour intravenous infusions).[26]
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AUC increased relative to dosage and did not
accumulate with repeated dosing in a phase I
dose-escalation trial in patients with hematologic
malignancies.[27]
Preclinical : The elimination half-life of bren-
tuximab vedotin in mice was approximately
5 days and the maximum tolerated dose was
>30mg/kg.[28]
2.2 Adverse Events
Phase III : In the interim results from the
ATHERA trial of brentuximab vedotin in patients
at high risk of residual Hodgkin lymphoma fol-
lowing ASCT, the most common adverse events
were peripheral sensory neuropathy (47%), fatigue
(46%), nausea (42%), upper respiratory tract infec-
tion (37%), and diarrhea (36%). The most com-
mon grade 3 or 4 adverse events were neutropenia
(20%), peripheral sensory neuropathy (8%), throm-
bocytopenia (8%), and anemia (6%).[9]
Phase II : Brentuximab vedotin demonstrated
a similar safety and tolerability profile to prior
clinical studies in a phase II trial of 102 patients
with relapsed or refractory Hodgkin lymphoma.
In this open-label trial, patients received bren-
tuximab vedotin (1.8mg/kg) every 3 weeks for a
maximum of 16 doses.[10]
Brentuximab vedotin was associated with
manageable adverse events in a phase II clinical
trial in 58 patients with relapsed or refractory
systemic ALCL. The most common adverse events
were nausea (38%), peripheral neuropathy (38%),
fatigue (34%), fever (33%), and diarrhea (29%).
The most common grade 3 or higher adverse
events were neutropenia (21%), peripheral neu-
ropathy (10%), thrombocytopenia (14%), and
anemia (7%).[4]
Phase I : In a phase I trial, brentuximab ve-
dotin exceeded a maximum tolerated dose at
1.4mg/kg and exhibited grade 3 dose-limiting tox-
icities of diarrhea and vomiting, and hyperglycemia
grade 4. Themost common drug-associated adverse
events were peripheral neuropathy, nausea, fatigue,
diarrhea, dizziness, and neutropenia; most were
grade 1 or 2 in severity. The trial enrolled patients
with relapsed or refractory CD30-positive lympho-
mas (n= 37) and brentuximab vedotin was admin-
istered weekly for 3 weeks in 28-day treatment cycles
at doses of 0.4–1.4mg/kg (30 minute or 2 hour
intravenous infusions).[26]
Brentuximab vedotin was generally well tol-
erated in a phase I trial among 44 evaluable
Table I. Features and properties
Alternate names cAC10-vcMMAE; SGN 35; SGN-35
Originator Seattle Genetics Inc.
Licensee(s) Millennium: The Takeda Oncology Company
Highest development phase III (Europe, US)
Active development indications Hodgkin lymphoma, Non-Hodgkin lymphoma
Class Auristatins, drug conjugates, monoclonal antibodies
Mechanism of action Tubulin polymerization inhibitors
CAS Registry number 914088-09-8
Route of administration IV
Pharmacodynamics Potent cytotoxic activity against CD30-expressing cells in vitro; associated with disease-free
survival mouse Hodgkin lymphoma model; dose-dependent antitumor activity in preclinical
models of anaplastic large cell lymphoma; has superior antitumor efficacy compared with non-
targeted drugs, in preclinical models of Hodgkin lymphoma
ATC codes
WHO ATC code L01 (Antineoplastic Agents), L01X-C (Monoclonal antibodies)
EphMRA ATC code L1 (Antineoplastics), L1X3 (Antineoplastic monoclonal antibodies)
Adverse events
Occasional Alopecia, diarrhea, fatigue, fever, injection-site reactions, musculoskeletal pain, nausea,
neutropenia, peripheral nervous system diseases, thrombocytopenia
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Table II. History
Event Date Update type Comment Update date
7 December 2010 Scientific Update Efficacy and adverse events data from a phase II trial in
anaplastic large cell lymphoma presented at the 52nd Annual
Meeting and Exposition of the American Society of Hematology
(ASH-2010)[4]
11 December 2010
6 December 2010 Scientific Update Interim efficacy and adverse events data from the phase III
AETHERA trial in Hodgkin lymphoma presented at the 52nd
Annual Meeting and Exposition of the American Society of
Hematology (ASH-2010)[9]
9 December 2010
5 December 2010 Scientific Update Additional efficacy data from a phase II trial in Hodgkin
lymphoma presented at the 52nd Annual Meeting and
Exposition of the American Society of Hematology
(ASH-2010)[37]
7 December 2010
11 October 2010 Scientific Update Efficacy data from a phase II trial (NCT00866047) in relapsed
and refractory non-Hodgkin lymphoma (anaplastic large cell
lymphoma) released by Seattle Genetics Inc. and Millennium:
The Takeda Oncology Company[14]
12 October 2010
27 September 2010 Scientific Update Efficacy data from a pivotal phase II trial in relapsed and
refractory Hodgkin lymphoma released by Seattle Genetics Inc.
and Millennium: The Takeda Oncology Company[10]
1 October 2010
8 June 2010 Scientific Update Interim efficacy and adverse events data from a clinical trial in
Hodgkin lymphoma and systemic anaplastic large cell
lymphoma (non-Hodgkin lymphoma) presented at the 46th
Annual Meeting of the American Society of Clinical Oncology
(ASCO-2010)[31]
15 June 2010
24 May 2010 Trial Update Seattle Genetics Inc. completes enrollment in its phase II trial
for relapsed/refractory anaplastic large cell lymphoma in the
US, EU, and Canada
26 May 2010
30 April 2010 Trial Update Seattle Genetics Inc. terminates the phase I trial of brentuximab
alone and in combination with gemcitabine for CD30-positive
hematologic malignancies
19 May 2010
10 April 2010 InThought Forecasts inThought Analysis for Hodgkin lymphoma updated 10 April 2010
30 March 2010 Phase Change Phase III clinical trials in Hodgkin lymphoma (patients at high
risk of residual Hodgkin lymphoma following autologous stem
cell transplant) in Europe (IV)
15 February 2011
30 March 2010 Phase Change Phase III clinical trials in Hodgkin lymphoma (patients at high
risk of residual Hodgkin lymphoma following autologous stem
cell transplant) in the US (IV)
30 March 2010
29 January 2010 Phase Change Phase I clinical trials (combination therapy) in Hodgkin
lymphoma in Canada (IV)
5 February 2010
29 January 2010 Phase Change Phase I clinical trials (combination therapy) in Hodgkin
lymphoma in the US (IV)
5 February 2010
16 December 2009 Licensing Status Seattle Genetics Inc. enters into a licensing agreement with
Millennium: The Takeda Oncology Company[1]
17 December 2009
8 December 2009 Scientific Update Efficacy, pharmacokinetic, and adverse events data from a
phase I trial in Hodgkin lymphoma and non-Hodgkin lymphoma
presented at the 51st Annual Meeting and Exposition of the
American Society of Hematology (ASH-2009)[26]
9 December 2009
5 December 2009 Scientific Update Updated interim efficacy and adverse events data from a phase
I trial in Hodgkin lymphoma and CD30-positive lymphoma
presented at the 51st Annual Meeting and Exposition of the
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Table II. Contd
Event Date Update type Comment Update date
8 September 2009 Scientific Update Further updated efficacy data from a phase I trial in Hodgkin
lymphoma and CD30-positive hematologic malignancies
released by Seattle Genetics Inc.[29]
16 September 2009
25 August 2009 Trial Update Seattle Genetics Inc. completes enrollment in its phase II trial
for brentuximab vedotin in Hodgkin lymphoma in the US,
Canada, and Europe
31 August 2009
25 July 2009 Trial Update Seattle Genetics Inc. initiates a phase II trial of retreatment in
relapsed/refractory Hodgkin lymphoma and systemic
anaplastic large cell lymphoma in the US[11]
28 July 2009
23 July 2009 Scientific Update Pharmacodynamics data from a preclinical trial in Hodgkin
lymphoma presented at the 100th Annual Meeting of the
American Association for Cancer Research (AACR-2009)[36]
23 July 2009
19 June 2009 Phase Change Phase II clinical trials in non-Hodgkin lymphoma in Canada (IV) 23 June 2009
2 June 2009 Scientific Update Interim efficacy and adverse events data from a phase I trial in
hematologic malignancies presented at the 45th Annual
Meeting of the American Society of Clinical Oncology
(ASCO-2009)[23]
8 June 2009
31 March 2009 Regulatory Status Brentuximab vedotin receives fast-track designation for
Hodgkin lymphoma (IV, infusion) in the US
1 April 2009
19 March 2009 Phase Change Phase II clinical trials in non-Hodgkin lymphoma in the EU (IV) 19 June 2009
19 March 2009 Phase Change Phase II clinical trials in non-Hodgkin lymphoma in the US (IV) 19 June 2009
20 February 2009 Phase Change Phase II clinical trials in Hodgkin lymphoma in Canada (IV) 23 February 2009
20 February 2009 Phase Change Phase II clinical trials in Hodgkin lymphoma in Europe (IV) 23 February 2009
20 February 2009 Phase Change Phase II clinical trials in Hodgkin lymphoma in the US (IV) 23 February 2009
20 February 2009 Trial Update Seattle Genetics Inc. initiates enrollment in a phase II trial for
Hodgkin lymphoma in Canada, Europe, and the US
23 February 2009
27 January 2009 Regulatory Status Brentuximab vedotin receives orphan drug status for
non-Hodgkin lymphoma in the EU
28 January 2009
27 January 2009 Regulatory Status Brentuximab vedotin receives orphan drug status for Hodgkin
lymphoma in the EU
28 January 2009
27 January 2009 Regulatory Status Brentuximab vedotin receives orphan drug status for
non-Hodgkin’s lymphoma in the US
28 January 2009
8 December 2008 Scientific Update Updated efficacy data from a phase I trial in hematologic
malignancies presented at the 50th Annual Meeting and
Exposition of the American Society of Hematology
(ASH-2008)[18]
10 December 2008
25 October 2008 Scientific Update Interim efficacy data from a phase I trial in hematologic
malignancies presented at the 20th-EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
(EORTC-NCI-AACR-2008)[19]
28 October 2008
24 October 2008 Scientific Update Pharmacodynamic data from a preclinical trial in hematologic
malignancies presented at the 20th-EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics
(EORTC-NCI-AACR-2008)[35]
12 November 2008
4 June 2008 Scientific Update Interim efficacy and adverse events data from a phase I trial in
Hodgkin lymphoma presented at the 44th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2008)[30]
11 June 2008
3 June 2008 Scientific Update Pharmacokinetics data from a phase I trial in Hodgkin
lymphoma presented at the 44th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2008)[27]
18 June 2008
Continued next page
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patients with Hodgkin lymphoma and CD30-
positive hematologic malignancies. The majority
of adverse events were grade 1 and 2, with the
most common being fatigue, fever, diarrhea, nau-
sea, and peripheral neuropathy. The maximum tol-
erated dose was defined as 1.8mg/kg. Patients re-
ceived doses of brentuximab vedotin every 3 weeks,
escalating from 0.1mg/kg to 3.6mg/kg. Dose-
limiting toxicities of hyperglycemia, prostatitis, and
neutropenic fever were observed at 2.7mg/kg. One
patient treated at 3.6mg/kg experienced fever,
neutropenia, and sepsis, and died 14 days after the
first dose of brentuximab vedotin. An additional
two patients developed a positive anti-therapeutic
antibody response to brentuximab vedotin in pre-
liminary analyses. Less than 10% of brentuximab
vedotin doses were delayed due to toxicity, pri-
marily neutropenia, at higher doses.[18,20,29,30]
In an open-label, uncontrolled, phase I trial
evaluating weekly dosing for refractory or
relapsed lymphoma (Hodgkin or systemic ALCL),
interim results for 35 evaluable patients showed
that brentuximab vedotin was generally well tol-
erated. The majority of adverse events were grade
1 and 2, with the most common being fatigue,
nausea, neutropenia, and peripheral neuropathy.
Patients received weekly doses of 0.4–1.4mg/kg,
for 3 of 4 weeks, for aminimumof two cycles.[22,23]
Preliminary data from 11 patients with Hodgkin
lymphoma (n = 9) and systemic ALCL (non-
Hodgkin lymphoma; n = 2) who received retreat-
ment with brentuximab vedotin monotherapy
have shown that the drug was well tolerated in
this setting. All drug-related adverse events were
grade 1 or 2, with the most common events being
peripheral neuropathy, hair loss (alopecia), joint
pain (musculoskeletal pain), and injection-site
irritation. Patients were heavily pretreated with a
range of 2–11 prior therapies. Five patients had
received a prior ASCT. Patients had achieved
Table II. Contd
Event Date Update type Comment Update date
31 March 2008 Trial Update Seattle Genetics Inc. initiates enrollment in a second phase I
trial for refractory or relapsed CD30-positive hematologic
malignancies in the US
2 April 2008
8 November 2007 Scientific Update Interim results from a phase I clinical trial in patients with
hematologic malignancies added to the adverse events and
cancer therapeutic trials sections[20]
8 November 2007
15 February 2007 Regulatory Status Brentuximab vedotin receives orphan drug status for Hodgkin
lymphoma in the US
15 February 2007
22 November 2006 Phase Change Phase I clinical trials in hematologic malignancies in US (IV) 22 November 2006
8 August 2006 Regulatory Status Seattle Genetic Inc. has filed an IND with the US FDA for the
treatment of Hodgkin lymphoma and other CD-positive
hematologic malignancies
8 August 2006
13 September 2005 Scientific Update Data presented at the 9th International Conference on
Malignant Lymphoma (ICML-2005) have been added to the
cancer pharmacodynamics section[34]
13 September 2005
15 June 2005 Scientific Update Preclinical data from a media release have been added to the
cancer pharmacodynamics section[33]
15 June 2005
15 July 2004 Licensing Status Seattle Genetics Inc. enters preferred provider agreement with
Albany Molecular Research for antibody-drug conjugate
manufacturing[2]
15 July 2004
12 September 2003 Scientific Update A preclinical study has been added to the adverse events
section[32]
12 September 2003
22 July 2003 Scientific Update Data presented at the 94th Annual Meeting of the American
Association for Cancer Research (AACR-20-03) have been
added to the cancer pharmacodynamics and pharmacokinetics
section[28]
22 July 2003
28 May 2003 Phase Change Preclinical trials in hematologic malignancies in the US (IV) 28 May 2003
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stable disease with decreasing tumor volume or
better during prior treatment with brentuximab
vedotin, discontinued treatment, and subsequent-
ly experienced disease progression.[31]
Animal Toxicology : In severe combined immu-
nodeficiency (SCID) mouse xenograft models of
ALCL or Hodgkin lymphoma, mice treated with




Preclinical : In vitro studies showed that the
peptide linkage in brentuximab vedotin was effi-
ciently cleaved by lyosomal proteases following
CD30 binding and internalization, releasing the
fully active drug compound, MMAE into the cell
cytosols. This resulted in growth arrest in G2/M
phase, apoptosis, and death. Brentuximab vedo-
tin had potent cytotoxic activity against CD30-
expressing cells (50% inhibitory concentration
[IC50] <10 ng/mL) but was 300-fold less potent
against antigen-negative cells. In vivo studies
showed that 80% of Hodgkin lymphoma and
ALCL xenografted mice treated with brentux-
imab vedotin survived disease-free at doses as low
as 1mg/kg.[28,32]
In preclinical models of ALCL, brentuximab
vedotin displayed IC50 values ranging from 3.9 to
15.8 ng/mL against CD30+ cell lines, and an IC50
>1000 ng/mL against the CD30 line WSU-NHL.
In a SCID mouse model of ALCL, brentuximab
vedotin exhibited dose-dependent antitumor ac-
tivity, with complete regressions achieved using doses
‡0.5mg/kg (with repeat dosing) and ‡1mg/kg (with
single dosing).[33,34]
Preclinical studies in animal models of Hodg-
kin lymphoma indicated that brentuximab ve-
dotin localized in tumor tissue and had potent
antitumor activity whether administered alone or
in combination with chemotherapy. When com-
bined with doxorubicin, bleomycin, vinblastine,
and dacarbazine, or gemcitabine, the antitumor
activity was markedly better than with brentux-
imab vedotin alone or chemotherapy alone.
Combination therapy was not associated with al-
terations in CD30 expression in tumors.[35]
Preclinical data have demonstrated the supe-
rior antitumor activity of brentuximab vedotin in
Hodgkin lymphoma, compared with that of sev-
eral non-targeted drugs, including vinorelbine,
vinblastine, and unconjugated MMAE. Due to
the targeting ability of brentuximab vedotin, con-
centrations of MMAE within tumors were up to
30-fold higher than the non-targeted drugs. Also,
MMAE concentrations in tumors were 1000-fold
greater than MMAE blood concentrations fol-
lowing brentuximab vedotin administration.[36]
2.4 Therapeutic Trials
2.4.1 Cancer
Phase III : In interim results from theATHERA
trial of brentuximab vedotin in patients at high
risk of residual Hodgkin lymphoma following
ASCT, 75% of patients achieved an objective
response, including 34% complete remissions,
Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Hodgkin lymphoma NE 63% (NYR) 10 Apr 2010
Non-Hodgkin lymphoma NE 31% (NYR) 30 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘A’ indicating significantly above average/likely to progress, ‘C’ indicating average,
and ‘F’ indicating significantly below average/unlikely to progress. ‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability of
approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate.
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and 40% partial remissions. The median duration
of response was 29 weeks by independent central
review and 47 weeks by investigator assessment.
Stable disease was observed in 22% of patients, of
which 3% had progressive disease and one patient
was not evaluable for response. Tumor reduc-
tions were achieved in 94% of patients. PFS
among all patients was 25 weeks by independent
review and 39 weeks by investigator assessment.
PFS among patients achieving a complete re-
mission and median overall survival had not yet
been reached at a median follow-up of approx-
imately 1 year.[9]
Phase II : Treatment with brentuximab vedo-
tin caused tumor reductions in 94% of patients
with relapsed or refractory Hodgkin lymphoma
in a pivotal, open-label phase II trial (n = 102).
Furthermore, 75% of patients had an objective
response that lasted for ‡6 months. Brentuximab
vedotin (1.8mg/kg) was administered every 3
weeks for up to a total of 16 doses.[10,14,37]
Results from a phase II single-arm clinical trial
with brentuximab vedotin (1.8mg/kg every 3weeks
for up to 16 total doses) in 58 patients with relapsed
or refractory systemic ALCL showed an objective
response in 86% of patients. Complete remission
was achieved in 53% of patients. The rate of partial
remissions was 33%, 3% of patients had stable
disease, and 5% had progressive disease.[4]
Phase I : In a phase I study, brentuximab vedo-
tin lead to an objective response rate in evaluable
patients of 46%, with 29% achieving complete
remission. Median duration of response to date
was at least 16 weeks with 15 patients continuing
treatment. The trial enrolled patients with re-
lapsed or refractory CD30+ lymphomas (n = 37)
and brentuximab vedotin was administered weekly
for 3 weeks in 28-day treatment cycles at doses of
0.4–1.4mg/kg (30 minute or 2 hour intravenous
infusions).[26]
In a phase I trial of brentuximab vedotin
among 44 evaluable patients with Hodgkin lym-
phoma and CD30+ hematologic malignancies,
17 patients achieved objective responses, includ-
ing nine complete responses and eight partial re-
sponses. A total of 18 additional patients had
stable disease and nine patients progressed. The
median duration of response was 22 weeks, with
11 responses ongoing at the time results were
published. Across all dose levels, 86% of the
42 patients who had at least one post-baseline
assessment achieved reductions in tumor volume.
Among 28 evaluable patients treated at doses of
1.2mg/kg and higher, 54% achieved an objective
response, including 32% with complete responses.
Additionally, 93% of these patients achieved tu-
mor reductions, and their mean PFS was greater
than 6 months. Patients received doses of bren-
tuximab vedotin every 3 weeks, escalating from
0.1mg/kg to 3.6mg/kg.[18,19,20,30] A further update
showed that the objective response rate (com-
bining all dose levels) was 39% (based on inves-
tigator assessment) and 41% (based on independent
review). In patients who received brentuximab
vedotin at doses of ‡1.2mg/kg, the overall res-
ponse rate was 54% (based on investigator
assessment) and 57% (based on independent re-
view). The median duration of response was ‡7.3
months and eight patients remained in ongoing
response.[29]
In an open-label, uncontrolled, phase I trial
evaluating weekly brentuximab vedotin dosing
for refractory or relapsed CD30+ lymphoma
(Hodgkin or systemic ALCL), interim results
showed that 16 of 35 evaluable patients achieved
objective responses (ten complete responses).
Eleven patients had stable disease and three had
progressive disease. The median duration of res-
ponse is ‡16 weeks, with 15 patients still receiving
treatment. Patients received weekly doses of
0.4–1.4mg/kg, for 3 of 4 weeks, for a minimum of
two cycles.[22,23]
Preliminary data from 11 patients with Hodgkin
lymphoma (n = 9) and systemic ALCL (non-
Hodgkin lymphoma; n = 2) who were retreated
with brentuximab vedotin monotherapy have
shown that objective responses were achieved
in seven retreated patients (64% of patients,
including two complete remissions and five par-
tial remissions). Tumor reductions were observed
in 10 of 11 retreated patients. All patients were
heavily pretreated (i.e. 2–11 prior therapies). Five
patients had received a prior ASCT. Patients had
achieved stable disease with decreasing tumor
volume or better during prior treatment with
brentuximab vedotin, discontinued treatment,
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and subsequently experienced disease progres-
sion. The time to objective response ranged from
5 to 15 weeks. Three patients showed stable dis-
ease and one had progressive disease. The dura-
tion of retreatment objective responses ranged
from <1 week (retreatment ongoing), to >58weeks.
Based on the small sample size, no difference in
duration of retreatment response between patients
with Hodgkin lymphoma and non-Hodgkin
lymphoma (ALCL) was observed. Retreatment is
ongoing in three patients.[31]
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